A quantitative review of nanotechnology‐based therapeutics for kidney diseases

Abstract

Kidney‐specific nanocarriers offer a targeted approach to enhance therapeutic efficacy and reduce off‐target effects in renal treatments. The nanocarriers can achieve organ or cell specificity via passive targeting and active targeting mechanisms. Passive targeting capitalizes on the unique physiological traits of the kidney, with factors like particle size, charge, shape, and material properties enhancing organ specificity. Active targeting, on the other hand, achieves renal specificity through ligand‐receptor interactions, modifying nanocarriers with molecules, peptides, or antibodies for receptor‐mediated delivery. Nanotechnology‐enabled therapy targets diseased kidney tissue by modulating podocytes and immune cells to reduce inflammation and enhance tissue repair, or by inhibiting myofibroblast differentiation to mitigate renal fibrosis. This review summarizes the current reports of the drug delivery systems that have been tested in vivo, identifies the nanocarriers that may preferentially accumulate in the kidney, and quantitatively compares the efficacy of various cargo‐carrier combinations to outline optimal strategies and future research directions.This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging Technologies

Reactive oxygen species-scavenging nanomaterials for the prevention and treatment of age-related diseases

“…NMs may accumulate in the kidneys due to their small size and unique surface properties. The extent of bioaccumulation due to repeated dosage over long periods of time is still unknown [ 358 ] [ 359 ].…”